Ulonivirine test in people with mild or moderate liver impairment
Part of Digestive system clinical trials.
This Phase 1 study tests how ulonivirine (a new medicine) behaves and is tolerated in people who have stable, mild-to-moderate liver impairment from chronic liver disease. The goal is to understand safety and drug handling in this specific liver condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic liver impairment (over 6 months) that’s stable, with no worsening episodes in the last 2 months (or you are a healthy control for this study).
- Your BMI is between 18.5 and 40 (inclusive).
- If you can get pregnant, you are not pregnant or breastfeeding, and you use an approved form of birth control or are not able to become pregnant; you also need a recent negative pregnancy test (for those who apply).
- You’re generally healthy enough to participate (not dealing with other serious illnesses that could interfere with results).
- You have not used certain hepatitis or immune-related medicines recently: no antiviral and/or immune modulating treatment for hepatitis B or C in the last 90 days.
- You have no key exclusions like HIV infection, known cancer, serious drug allergy, or prior participation in another study within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called eloralintide in people with healthy livers and in those with mild, moderate, or severe liver damage. It helps researchers learn how the liver affects the medicine in the body.
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This research study tests how a new drug called ulonivirine works with methadone in people who are stable on methadone treatment. The goal is to understand if these two medications can be safely used together without problems.
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
This study tests how the body processes the drug inavolisib when taken by people with moderate or severe liver problems compared to those with healthy livers. It helps doctors understand the right dose for patients with liver impairment.
Hear when a new Hepatic Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.